Concepedia

What is the Cost of Diagnosis and Management of Drug Resistant Tuberculosis in South Africa?

Anil Pooran, Elize Pieterson, Malika Davids, Grant Theron, Keertan Dheda

PLoS ONE · 2013 · 231 citations · 28 references

DOIFull text

Open access

Abstract

Although DR-TB forms a very small proportion of the total case burden it consumes a disproportionate and substantial amount of South Africa's total annual TB budget. These data inform rational resource allocation and selection of management strategies for DR-TB in high burden settings.

References

28

WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update

Dennis Falzon, E. Jaramillo, Holger J. Schünemann et al. · European Respiratory Journal · 2011 · 1.1K citations · Full text

, , +22

Cost-effectiveness analysis.

Ray Robinson · BMJ · 1993 · 818 citations · Full text

, , +13

Evaluation of the Xpert MTB/RIF Assay for the Diagnosis of Pulmonary Tuberculosis in a High HIV Prevalence Setting

Grant Theron, Jonny Peter, Richard N. van Zyl-Smit et al. · American Journal of Respiratory and Critical Care Medicine · 2011 · 308 citations

Early treatment outcomes and HIV status of patients with extensively drug-resistant tuberculosis in South Africa: a retrospective cohort study

Keertan Dheda, Karen Shean, Alimuddin Zumla et al. · The Lancet · 2010 · 248 citations

, , +8

Clinical and Economic Impact of Adverse Drug Reactions in Hospitalized Patients

Dong‐Churl Suh, Betsy S Woodall, Soung-Kook Shin et al. · Annals of Pharmacotherapy · 2000 · 219 citations